PT2307000E - Associação de pilocarpina e metimazol para o tratamento da doença de charcot-marie-tooth e patologias relacionadas - Google Patents

Associação de pilocarpina e metimazol para o tratamento da doença de charcot-marie-tooth e patologias relacionadas Download PDF

Info

Publication number
PT2307000E
PT2307000E PT97658710T PT09765871T PT2307000E PT 2307000 E PT2307000 E PT 2307000E PT 97658710 T PT97658710 T PT 97658710T PT 09765871 T PT09765871 T PT 09765871T PT 2307000 E PT2307000 E PT 2307000E
Authority
PT
Portugal
Prior art keywords
methimazol
pilocarpin
combination
related disorders
treating charcot
Prior art date
Application number
PT97658710T
Other languages
English (en)
Inventor
Ilya Chumakov
Daniel Cohen
Oxana Guerassimenko
Serguei Nabirochkin
Nathalie Cholet
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of PT2307000E publication Critical patent/PT2307000E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT97658710T 2008-06-18 2009-06-17 Associação de pilocarpina e metimazol para o tratamento da doença de charcot-marie-tooth e patologias relacionadas PT2307000E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08305280A EP2135607A1 (en) 2008-06-18 2008-06-18 Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders

Publications (1)

Publication Number Publication Date
PT2307000E true PT2307000E (pt) 2014-05-06

Family

ID=40007419

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97658710T PT2307000E (pt) 2008-06-18 2009-06-17 Associação de pilocarpina e metimazol para o tratamento da doença de charcot-marie-tooth e patologias relacionadas

Country Status (21)

Country Link
US (2) US8716269B2 (pt)
EP (2) EP2135607A1 (pt)
JP (1) JP5677946B2 (pt)
KR (2) KR101663998B1 (pt)
CN (1) CN102065854B (pt)
AU (1) AU2009259336B2 (pt)
BR (1) BRPI0915308A2 (pt)
CA (1) CA2727064C (pt)
CY (1) CY1115360T1 (pt)
DK (1) DK2307000T3 (pt)
EA (1) EA023380B1 (pt)
ES (1) ES2460617T3 (pt)
HR (1) HRP20140354T1 (pt)
IL (1) IL209816A0 (pt)
MX (1) MX2010013984A (pt)
NZ (1) NZ589940A (pt)
PL (1) PL2307000T3 (pt)
PT (1) PT2307000E (pt)
SI (1) SI2307000T1 (pt)
WO (1) WO2009153291A1 (pt)
ZA (1) ZA201100459B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065038A1 (en) * 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
EP2263665A1 (en) * 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
WO2012112933A1 (en) 2011-02-18 2012-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
UA113165C2 (xx) 2011-03-01 2016-12-26 Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
EP2705842A1 (en) 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
KR101918745B1 (ko) 2011-03-01 2018-11-15 파넥스트 바클로펜 및 아캄프로세이트에 기초한 신경 장애의 치료
LT3003268T (lt) 2013-06-05 2018-12-10 Pharnext Stabilūs peroraliniai tirpalai, skirti kompleksiniam aktyviam farmaciniam ingredientui (api)
CA2938361A1 (en) 2014-02-11 2015-08-20 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
SG11201606485VA (en) * 2014-02-24 2016-09-29 Pharnext New compositions for treating mechanical neuronal injuries
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
CN111658643B (zh) * 2020-07-31 2021-12-07 西安交通大学医学院第一附属医院 雷帕霉素在难治性Graves病中的制药应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721263A (en) 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
US6573251B2 (en) 1994-03-30 2003-06-03 Denis Barritault Drug and pharmaceutical composition for the treatment of lesions of the nervous system and fractions enriched in heparan sulfate
TW427904B (en) 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
AU9187598A (en) 1997-09-30 1999-04-23 Daiichi Pharmaceutical Co., Ltd. Oral preparation
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
CA2345642A1 (en) * 1998-10-02 2000-04-13 Celtrix Pharmaceuticals, Inc. Methods for the treatment of non-thyroid disorders
WO2001058476A2 (en) 2000-02-11 2001-08-16 The European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
GEP20063811B (en) 2001-07-19 2006-05-10 Pharmacia Corp Combination of Aldosterone Receptor Antagonist and HMG COA Reductase Inhibitor
AU2003222009A1 (en) 2002-03-18 2003-10-08 Pharmacia Corporation Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative
US20040102525A1 (en) 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
FR2842422B1 (fr) 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
CA2495917A1 (en) * 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
EP2465537B1 (en) 2002-10-10 2016-06-29 ONO Pharmaceutical Co., Ltd. Microspheres comprising ONO-1301
EP1837034A4 (en) 2004-11-30 2009-08-05 Anges Mg Inc MEDICATION FOR ALZHEIMER'S DISEASE
GB0509052D0 (en) 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
US20080188510A1 (en) 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
US20100029654A1 (en) 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
KR20090026275A (ko) 2006-07-06 2009-03-12 로스캄프 리서치 엘엘씨 베타-아밀로이드 생성을 억제하기 위한 화합물 및 그의 조합물, 및 그의 사용 방법
PL2157973T3 (pl) 2007-05-22 2015-12-31 Otsuka Pharma Co Ltd Lek zawierający pochodną karbostyrylu i donepezil do leczenia choroby Alzheimera
EP2217564A1 (en) 2007-09-07 2010-08-18 XenoPort, Inc. Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
US20100137442A2 (en) 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
MX2010011880A (es) 2008-04-29 2011-05-25 Pharnext Nuevos enfoques terapeuticos para tratar la enfermedad del alzheimer y trastornos relacionados mediante una modulacion de la respuesta de estres celular.
CN102065898B (zh) 2008-04-29 2015-08-26 法奈科斯公司 通过调节血管发生治疗阿茨海默病和相关病症的新治疗手段
NZ589304A (en) 2008-04-29 2012-03-30 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
RU2489433C9 (ru) 2008-11-27 2014-06-10 Нэшнл Юниверсити Корпорейшн Кагава Юниверсити Производное циклобутилпурина, агент, активирующий ангиогенез, агент, активирующий образование просвета, агент, активирующий рост нейронов, и лекарственное средство
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
KR101918745B1 (ko) 2011-03-01 2018-11-15 파넥스트 바클로펜 및 아캄프로세이트에 기초한 신경 장애의 치료
CN103288957B (zh) 2012-12-21 2015-01-28 百奥泰生物科技(广州)有限公司 一种抑制肿瘤生长的抗体药物衍生物及其制备方法和用途

Also Published As

Publication number Publication date
EP2135607A1 (en) 2009-12-23
IL209816A0 (en) 2011-02-28
US20120040940A1 (en) 2012-02-16
AU2009259336A1 (en) 2009-12-23
KR20160062222A (ko) 2016-06-01
NZ589940A (en) 2012-05-25
EP2307000B1 (en) 2014-02-26
CA2727064A1 (en) 2009-12-23
ES2460617T3 (es) 2014-05-14
BRPI0915308A2 (pt) 2015-10-27
CA2727064C (en) 2016-11-01
JP2011524878A (ja) 2011-09-08
CN102065854B (zh) 2014-03-12
CY1115360T1 (el) 2017-01-04
CN102065854A (zh) 2011-05-18
PL2307000T3 (pl) 2014-09-30
US20140235599A1 (en) 2014-08-21
US8716269B2 (en) 2014-05-06
EA023380B1 (ru) 2016-05-31
MX2010013984A (es) 2011-04-04
AU2009259336B2 (en) 2015-01-29
KR20110031448A (ko) 2011-03-28
EA201170043A1 (ru) 2011-08-30
HRP20140354T1 (hr) 2014-07-18
EP2307000A1 (en) 2011-04-13
SI2307000T1 (sl) 2014-07-31
JP5677946B2 (ja) 2015-02-25
US9597297B2 (en) 2017-03-21
KR101663998B1 (ko) 2016-10-25
WO2009153291A1 (en) 2009-12-23
ZA201100459B (en) 2012-12-27
DK2307000T3 (da) 2014-04-14

Similar Documents

Publication Publication Date Title
ZA201100459B (en) Combination of pilocarpin and methimazol for treating charcot-marietooth disease and related disorders
HRP20181608T1 (hr) Korištenje inhibitora pde7 u liječenju bolesti kretanja
HK1158172A1 (en) Compounds for treating ophthalmic diseases and disorders
EP2293800A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF EARLIER DISEASES
ZA201103759B (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
EP2259679A4 (en) METHOD FOR THE TREATMENT OF CALLIQUE CLEANING DISORDERS
EP2260109A4 (en) METHODS AND COMPOSITIONS BASED ON MICRO-RNA FOR DIAGNOSING, PROGNOSING AND TREATING PROSTATE-RELATED DISORDERS
ZA201100482B (en) Pyrazolopyrimidines and their use for the treatment of cns disorders
GB0703909D0 (en) Treatment of anxiety disorders
EP2509596A4 (en) COMPOUNDS AND METHOD FOR THE TREATMENT OF EYE DISEASES
EP2139475A4 (en) USE OF PDE7 INHIBITORS IN THE TREATMENT OF
GB0915259D0 (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders
EP2328584A4 (en) TREATMENT OF NEUROLOGICAL DISORDERS USING HUPERZINE
IL209417A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
IL210558A0 (en) Treatment of anxiety disorders
EP2421532A4 (en) SPIPERON DERIVATIVES AND METHOD FOR THE TREATMENT OF ILLNESSES
IL207906A0 (en) Treatment for ocular-related disorders
PT2278962E (pt) Métodos para o tratamento de desordens dermatológicas
HK1145282A1 (en) Treatment of sleep disorders
GB0814043D0 (en) The treatment of skin disorders
GB0819446D0 (en) Treatment of inflammatory disorders
EP2124957A4 (en) METHOD FOR THE TREATMENT OF VITAL DISEASES
ZA201100325B (en) Treatment of anxiety disorders
IL208831A0 (en) Methods of treating ophthalmic disorders